BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 3, 2026
Breaking News: Read BioWorld's AACR 2026 coverageBreaking News: Read BioWorld's AACR 2026 coverageBreaking News: Best of BioWorld: Q1
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Cancer

Baylor College of Medicine patents NTRK inhibitors

Feb. 20, 2024
Baylor College of Medicine has disclosed new neurotrophic receptor tyrosine kinase (NTRK) inhibitors that are reported to be useful for the treatment of cancer, endometriosis, female infertility, pelvic pain and inflammatory disorders.
Read More
Colorectal cancer illustration
Cancer

IMPDH2 as new therapeutic target for oxaliplatin resistance in colorectal cancer

Feb. 20, 2024
Since oxaliplatin is currently one of the most effective chemotherapeutic drugs used in the treatment of colorectal cancer (CRC), resistance to oxaliplatin usually leads to therapeutic failure and poor prognosis in CRC patients. A team at The Sixth Affiliated Hospital - Sun Yat-sen University aimed to investigate the mechanisms of metabolic reprogramming in oxaliplatin resistance in CRC.
Read More
Silhouette made of crumpled paper illustrating depression
Neurology/Psychiatric

Dual cannabinoid and serotonin receptor agonist shows antidepressant properties

Feb. 20, 2024
Cannabinoid CB2 receptor and serotonin 5-HT1A receptor agonists have emerged as therapeutic options for their antidepressive and anxiolytic properties, apart from being linked to synergistic antinociceptive activity when used in combination in animal tests.
Read More
A fundus image of a healthy retina.
Ocular

Novel inducible mouse model of North Carolina macular dystrophy

Feb. 20, 2024
At the recent Macula Society Meeting, researchers from the Molecular Insight Research Foundation reported on the creation of a novel murine model of North Carolina macular dystrophy.
Read More
CAR T cell attacking cancer cells
Immuno-oncology

STING agonist IMSA-101 improves CAR T therapy trafficking into tumor

Feb. 20, 2024
Immunesensor Therapeutics Inc. has presented preclinical data on the stimulator of interferon genes (STING) agonist IMSA-101 which is designed to modify the tumor microenvironment in solid tumors and thus improve the trafficking and infiltration of CAR T-cell therapy into the tumor.
Read More
Cancer

TACC3 inhibition enhances antitumor efficacy of T-DM1 in HER2-positive breast cancer

Feb. 20, 2024
In a recent study, scientists from Medical University of South Carolina aimed to evaluate whether immunogenic cell death (ICD) can trigger resistance to anticancer therapies and explore potential therapeutic opportunities to revive ICD and restore drug sensitivity.
Read More
Artistic rendering of the KRAS protein.
Drug Design, Drug Delivery & Technologies

Zapata AI announces use of quantum-enhanced generative AI to generate novel KRAS inhibitors

Feb. 20, 2024
Zapata Computing Inc. (Zapata AI) scientists have demonstrated the first instance of a generative model running on quantum hardware outperforming state-of-the-art classical models in generating viable cancer drug candidates.
Read More
Illustration of tau accumulating in a neuron cell.
Neurology/Psychiatric

Voyager Therapeutics reports updates from preclinical programs targeting tau for Alzheimer’s disease

Feb. 20, 2024
Voyager Therapeutics Inc. has announced new data from two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease.
Read More
Cardiovascular

C3 inhibitor CP40-KK protects rats from PAH development

Feb. 20, 2024
Pulmonary arterial hypertension (PAH) is a severe condition characterized by vasoconstriction and remodeling of the small pulmonary arteries, driven by a complement-dependent activation of macrophages, for which an effective treatment is lacking. Chinese researchers have investigated the potential of a complement C3 inhibitor polypeptide, CP40-KK, as an approach for treating PAH. To do this, they used a model in which PAH was induced in rats by monocrotaline.
Read More
AI generated illustration of a brain on fire
Immune

Finding the good in autoantibodies could REAP broad benefits

Feb. 20, 2024
By Anette Breindl
Autoantibodies call to mind disease – autoimmune disease, to be exact. But the physiological roles of autoantibodies are, at the very least, more complex than this view accounts for. “The autoantibody reactome is extraordinary,” Aaron Ring told BioWorld. “Nearly everyone has autoantibodies, whether they know it or not.”
Read More
Previous 1 2 … 788 789 790 791 792 793 794 795 796 … 18056 18057 Next

Popular Stories

  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • Nerves within a melanoma tumor

    Innervation can slow, as well as speed, tumor growth, study finds

    BioWorld
    Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing